Actavis Said to Have Spurned $15 Billion Offer

Actavis Said to Have Spurned $15 Billion Offer Play

May 14 (Bloomberg) -- Actavis rejected a cash-and-stock offer from fellow generic drugmaker Mylan for $15 billion, deciding instead to pursue talks to take over Warner Chilcott, said people familiar with the matter. Bloomberg's Jeff McCracken reports on Bloomberg Television's "Street Smart." (Source: Bloomberg)

Feed Most Popular

  • On Air Now

    Bloomberg West Watch Now

  • Next

    Money Clip

blog comments powered by Disqus